enVVeno Medical Corporation logo

enVVeno Medical Corporation

NVNO | NASDAQ
Chart Builder DCF Calculator
$9.05
+$0.08 (+0.84%)
At close: Sep 21, 2026, 4:00 PM ET
$9.05
$0 (0.00%)
After-hours: Sep 21, 2026, 7:30 PM ET

Company Profile

enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.

Key Executives

Name Position
Robert A. Berman Chief Executive Officer & Director
Hamed Alavi Senior Vice President & Chief Technology Officer
Jennifer Bright Chief Financial Officer
Avi Sharma Senior Vice President of Clinical, Regulatory & Quality
Marc H. Glickman Senior Vice President & Chief Medical Officer
Sandy Prietto Vice President of Marketing

Latest SEC Filings

Date Type Title
Aug 21, 2026 S-3 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jul 30, 2026 10-Q Quarterly Report
Jul 14, 2026 8-K Current Report
Jun 12, 2026 4 Filing
May 15, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
May 15, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
May 06, 2026 10-Q Quarterly Report
Apr 29, 2026 8-K Current Report
Mar 26, 2026 S-8 Filing
View All SEC Filings
enVVeno Medical Corporation
enVVeno Medical Corporation logo
Country United States
IPO Date May 30, 2018
Industry Medical - Devices
Sector Healthcare
Employees 33
CEO Robert A. Berman

Contact Details

70 Doppler Irvine, California 92618 United States

Stock Details

Ticker Symbol NVNO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001661053
CUSIP Number 29415J205
ISIN Number US29415J2050
SIC Code 3841

© 2026 bestshares.com. All rights reserved.